# Aurinia Pharmaceuticals share price today (Aurinia Pharmaceuticals Inc., AUPH)

> Aurinia Pharmaceuticals Inc.'s results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 20% of past readings. AUPH · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/auph

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $16.21 (+11.0% in a year)
- P/E: 7.0× (lower than 80% of the last 1 year)
- Revenue (Jun 2026): $83.2 M (+18.9% on a year ago)
- Profit (Jun 2026): $37.4 M (+73.9% on a year ago)
- Operating margin: 55.7% (+26.9 points on a year ago)
- ROE: 49%, FY25
- ROIC: 71.3%, against a 12.9% cost of capital: +58.4 points
- Profit that came in as cash: 61%, last 2 years

The main question: yearly earnings per share moved +5,075.0% while the share price moved +11.0%. ## What is the Aurinia Pharmaceuticals share price today? Aurinia Pharmaceuticals Inc.'s share price was $16.21 at the close on 5 November 2026. It has been rising for 14 weeks. That is 3.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $14 and $17, and at that close it sat 69% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 5 weeks in a row. Over the last 10 years the share price moved +423% while the S&P 500 moved +245%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Aurinia Pharmaceuticals pay? Aurinia Pharmaceuticals Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Aurinia Pharmaceuticals on? Aurinia Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Aurinia Pharmaceuticals profitable? Aurinia Pharmaceuticals Inc. earned $37.4 M of net profit in the Jun 2026 quarter, +73.9% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY25 profit was $287 M. That is 45.0% of the quarter's revenue. The same quarter a year earlier earned $21.5 M. 3 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $287 M (+4,893.1% on the year before). Why profit moved: revenue changed +18.9% on a year earlier and the margin moved +26.9 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +3,723.1% and revenue +20.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Aurinia Pharmaceuticals make, and is it growing? Aurinia Pharmaceuticals Inc. reported $83.2 M of revenue in the Jun 2026 quarter, +18.9% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 4 years it has grown 57.8% a year on average. The last full year, FY25, came in at $283 M. The last four reported quarters add to $312 M. FY25 revenue was $283 M, +20.4% on the year before. Recent pace: the last four quarters grew +20.1% on average, against 57.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +19.8%, against +22.6% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Aurinia Pharmaceuticals keep? Aurinia Pharmaceuticals Inc.'s operating margin was 55.7% in the Jun 2026 quarter, 26.9 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −396.3% and 41.1%. The latest quarter is above every full year in that period. Across 5 years it has been between −396.3% and 41.1%, and FY25's 41.1% is the highest of them. Why the margin moved: operating margin changed +26.9 percentage points on the year while gross margin changed −1.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Aurinia Pharmaceuticals' profit turning into cash? Over the last 2 years, 61% of Aurinia Pharmaceuticals Inc.'s reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in $136 M of operating cash against $287 M of profit. After $252 K of spending on assets, $135 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Aurinia Pharmaceuticals' cash go? Aurinia Pharmaceuticals Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.3 M on assets over the last 3 years. Averaged over those years that is 0.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.3 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Aurinia Pharmaceuticals' P/E ratio, and how does it compare with its own history? Aurinia Pharmaceuticals Inc.'s P/E is 7.0×, near the low end of its own history: it has been lower only 20% of the time. Its usual P/E (the middle reading) is 20.3×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +5,075.0% while the price moved +11.0%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Aurinia Pharmaceuticals business getting better or worse? Aurinia Pharmaceuticals Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Aurinia Pharmaceuticals earn on its capital? Aurinia Pharmaceuticals Inc. earned a ROE of 49% in FY25. That is up from a low of −38% in FY21. Its return on capital used (ROIC) is 58.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 101.5% net margin and 0.38× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 101.5% net margin × 0.38× asset turnover × 1.29× leverage (assets divided by equity) ≈ 49.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 71.3% − 12.9% = +58.4 percentage points. The 12.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 71.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 65.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Aurinia Pharmaceuticals have too much debt? Aurinia Pharmaceuticals Inc. has total debt of $64.1 M against shareholder equity of $615 M as of Jun 2026, so its debt is 0.10× its equity, which is very little. Year by year, that ratio went from 0.02 in FY21 to 0.13 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Aurinia Pharmaceuticals shareholding pattern? 6.0% of Aurinia Pharmaceuticals Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 8.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Aurinia Pharmaceuticals from balance-sheet trouble? For Aurinia Pharmaceuticals Inc., the Z-score is 7.95. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 7.95 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Aurinia Pharmaceuticals rank in its industry? There is no score against its industry: Aurinia Pharmaceuticals Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Aurinia Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Aurinia Pharmaceuticals in size? Aurinia Pharmaceuticals is the 72nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Celldex Therapeutics, Inc., Septerna, Inc. and Recursion Pharmaceuticals, Inc. Just below it: Lakefront Biotherapeutics NV, Immunome, Inc. and Zymeworks Inc. ### Biotechnology companies close in size

1. [Celldex Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/cldx) $2.2 billion
2. [Septerna, Inc.](https://www.sectoralpha.in/us/stocks/sepn) $2.2 billion
3. [Recursion Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rxrx) $2.2 billion
4. Aurinia Pharmaceuticals Inc. $2.2 billion
5. [Lakefront Biotherapeutics NV](https://www.sectoralpha.in/us/stocks/lkft) $2.2 billion
6. [Immunome, Inc.](https://www.sectoralpha.in/us/stocks/imnm) $2.1 billion
7. [Zymeworks Inc.](https://www.sectoralpha.in/us/stocks/zyme) $2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Immunome, Inc.](https://www.sectoralpha.in/us/stocks/imnm) $2.3 billion · Biotechnology
2. [Custom Truck One Source, Inc.](https://www.sectoralpha.in/us/stocks/ctos) $2.3 billion · Rental & Leasing Services
3. Aurinia Pharmaceuticals Inc. $2.3 billion
4. [Rogers Corporation](https://www.sectoralpha.in/us/stocks/rog) $2.3 billion · Electronic Components
5. [Enterprise Financial Services Corp](https://www.sectoralpha.in/us/stocks/efsc) $2.3 billion · Banks - Regional

## What else do people ask about Aurinia Pharmaceuticals? ### What were Aurinia Pharmaceuticals's latest quarterly results? Aurinia Pharmaceuticals Inc. reported revenue of $83.2 M and net profit of $37.4 M for the Jun 2026 quarter. Revenue rose 18.9% and profit rose 73.9% compared with a year earlier. Earnings per share were $0.28. The operating margin was 55.7%, 26.9 percentage points higher than a year earlier (as of 5 November 2026). ### What is Aurinia Pharmaceuticals's market cap? Aurinia Pharmaceuticals Inc.'s market capitalisation is $2.2 B at a stock price of $16.21. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Aurinia Pharmaceuticals performing? Aurinia Pharmaceuticals Inc.'s share price has been rising for 14 weeks. In its latest quarter, revenue rose 18.9% and profit rose 73.9% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 5 weeks running (as of 5 November 2026). ### Will Aurinia Pharmaceuticals's stock price go up? This page does not forecast Aurinia Pharmaceuticals Inc.'s stock price. What it shows instead: the stock price is $16.21, and it has been rising for 14 weeks. Its P/E of 7.0× is higher than 20% of its own last 2 years (as of 5 November 2026). ### Does Aurinia Pharmaceuticals have too much debt? No, Aurinia Pharmaceuticals Inc. has little debt: its debt is 0.09× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 5 November 2026). ### Where is Aurinia Pharmaceuticals in its business cycle? Aurinia Pharmaceuticals Inc.'s FY25 operating margin was 41.1%, against a 5-year range of −396.3% to 41.1%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 55.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Aurinia Pharmaceuticals story? The main question: yearly earnings per share moved +5,075.0% while the share price moved +11.0%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Aurinia Pharmaceuticals a stock worth studying right now? What the numbers show: Aurinia Pharmaceuticals Inc.'s results are improving, while its P/E is near the low end of its own history over 1 year, higher than only 20% of past readings. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.